HUTCHMED (China) Ltd Files Routine 6-K
Ticker: HMDCF · Form: 6-K · Filed: Jan 2, 2025 · CIK: 1648257
Sentiment: neutral
Topics: disclosure, foreign-private-issuer, routine-filing
TL;DR
HUTCHMED filed a 6-K, standard disclosure for foreign issuers. No major news.
AI Summary
HUTCHMED (China) Limited filed a Form 6-K on January 2, 2025, reporting as a foreign private issuer. The filing does not contain specific financial figures or operational updates but serves as a routine disclosure for the month of January 2025. The company, previously known as Hutchison China MediTech Ltd, is incorporated in E9 and headquartered in Hong Kong.
Why It Matters
This filing indicates HUTCHMED is meeting its ongoing disclosure obligations as a foreign private issuer, which is important for investors tracking regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine filing with no new material information, financial data, or operational changes disclosed.
Key Players & Entities
- HUTCHMED (China) Limited (company) — Filer
- Hutchison China MediTech Ltd (company) — Former company name
- 20250102 (date) — Filing date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information which the registrant may be required to disclose or make public pursuant to the laws of its home country or which it may make public or permit to be made public.
When was this Form 6-K filed?
This Form 6-K was filed on January 2, 2025.
What was HUTCHMED's previous company name?
HUTCHMED's former company name was Hutchison China MediTech Ltd.
Where is HUTCHMED's principal executive office located?
HUTCHMED's principal executive office is located at 48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.
Does HUTCHMED file annual reports under Form 20-F or 40-F?
HUTCHMED indicates it files annual reports under cover of Form 20-F.
Filing Stats: 207 words · 1 min read · ~1 pages · Grade level 14.3 · Accepted 2025-01-02 06:06:11
Key Financial Figures
- $608 million — cement relating to HUTCHMED announces US$608 million divestment of non-core joint venture E
Filing Documents
- hcm-20250102x6k.htm (6-K) — 21KB
- hcm-20250102xex99d1.htm (EX-99.1) — 30KB
- hcm-20250102xex99d2.htm (EX-99.2) — 173KB
- hcm-20250102xex99d3.htm (EX-99.3) — 52KB
- hcm-20250102xex99d1001.gif (GRAPHIC) — 4KB
- hcm-20250102xex99d2001.gif (GRAPHIC) — 4KB
- hcm-20250102xex99d3001.gif (GRAPHIC) — 4KB
- 0001648257-25-000002.txt ( ) — 294KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant's name into English) 48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F HUTCHMED (CHINA) LIMITED Form 6-K EXHIBIT INDEX Exhibit No. Description Exhibit 99.1 Announcement relating to HUTCHMED announces US$608 million divestment of non-core joint venture Exhibit 99.2 Overseas regulatory announcement on disposal transaction Exhibit 99.3 Press release relating to HUTCHMED announces NDA acceptance in China with priority review status for ORPATHYS and TAGRISSO combination in lung cancer patients with MET amplification after progression on first-line EGFR inhibitor therapy 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. HUTCHMED (CHINA) LIMITED By: /s/ Johnny Cheng Name: Johnny Cheng Title: Chief Financial Officer Date: January 2, 2025 3